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Purpose: Posterior Polymorphous Dystrophy (PPCD) is a genetically heterogeneous corneal dystrophy, with linkage to
three different chromosomal loci, with several genes in these loci being implicated. The role of both VSX1 and COL8A2
in PPCD remains controversial but recent work suggests that mutations in the transcription factor gene ZEB1/TCF8 account
for disease in up to 30% of subjects, with a significant association with connective tissue abnormalities. This study aimed
to determine the phenotype and contribution of ZEB1 mutations in a New Zealand PPCD population
Methods: Following informed consent, 11 probands with PPCD underwent extensive clinical characterization; including
a questionnaire to determine birth history, general health, and the incidence of connective tissue abnormalities, slit lamp
examination, photography and in vivo confocal microscopy. Family members were recruited where available. Biological
specimens underwent mutational analysis of all nine coding exons of ZEB1.
Results: ZEB1 mutational analysis identified one mutation in the 11 probands (9.1%), a novel mutation in the initiating
methionine of exon 1, c.1A→G that results in the protein change p.Met1Val, with resultant aberrant initiation of translation.
This mutation segregated with disease in the family, and was not present in 100 control chromosomes. No other ZEB1
mutations were observed in this cohort.
Conclusion: Recent studies suggest that ZEB1 mutations may account for PPCD in 18 to 30% of cases, with the majority
of the mutations in exons 5 and 7. Clinical and molecular analyses in this New Zealand cohort show a much lower incidence
of ZEB1 sequence change, confirming the genetic heterogeneity of PPCD. We also report identification of a novel mutation
in the initiating methionine that removes the Kozak sequence, thereby altering the site of initiation translation.
Posterior Polymorphous Corneal Dystrophy (PPCD) is a
frequently  asymmetric  autosomal  dominant  corneal
dystrophy with characteristic involvement of the Descemet
membrane  and  the  endothelium.  However,  marked
phenotypic expressivity and variation is reported and although
most affected individuals are often asymptomatic, symptoms
may include visual blurring, glare, and rarely the need for
penetrating keratoplasty [1]. PPCD has been linked to three
chromosomal loci: PPCD1 (OMIM 122000) on chromosome
20p11.2-q11.2,  PPCD2  (OMIM  609140)  on  chromosome
1p34.3 – p32.3, and PPCD3 (OMIM 609141) on chromosome
10p11.2. Putative genes at each locus have been identified but
some controversy exists regarding the role of the homeobox
gene,  VSX1  in  PPCD1.  Mutations  in  this  gene  were
demonstrated segregating with disease in three PPCD families
[1,2], but other studies have not replicated these results [3,4],
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suggesting a different and yet unidentified gene within the
PPCD1 locus is responsible for this disease [4-6]. The interval
was recently reduced to 10 cM between markers D20S182 and
D20S195 [6]. Similarly the COL8A2 gene within the PPCD2
locus  was  implicated  in  this  disorder  [7],  as  well  as
contributing to the pathogenesis of Fuchs’ endothelial corneal
dystrophy (FECD). The contribution of this gene has also been
called into question as further studies have failed to identify
mutations within analyzed PPCD or FECD cohorts [8-10].
Three  recent  studies  investigating  a  more  promising
candidate gene at the PPCD3 locus demonstrated disease-
causing mutations in the zinc finger E-box binding homeobox
1 gene ZEB1 (OMIM 189909), previously known as TCF8
[11-13]. A mutation was confirmed in the original family
described by Moroi et al. [14] that linked to this locus [15].
These series also expanded the phenotypic spectrum of PPCD
by observing a high incidence of non-ocular connective tissue
abnormalities occurring in association with ZEB1 mutations
and PPCD, predominantly inguinal and abdominal hernias.
Marked corneal phenotypic heterogeneity in PPCD exists
with the clinical spectrum manifesting as nodular, vesicular,
or blister like lesions within the endothelium, which may be
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2544isolated,  cluster,  or  form  curvilinear  tracks  -  a  band  or
“railroad  track”  appearance  delineated  by  strips  of
condensation  and  diffuse  irregularities  in  the  Descemet
membrane, and a more diffuse type with variable amounts of
grey  tissue  and  irregularity  at  the  level  of  the  Descemet
membrane. Peripheral iridocorneal adhesions and elevated
intraocular pressure are also observed [16,17].
The characteristic histological features demonstrate the
transformation  of  the  endothelial  cell  phenotype  to  an
epithelial-like cell with desmosomes, stratification, layering,
and microvilli [18] but as the majority of cases do not require
surgical intervention, tissue specimens are rarely available for
histological  analysis.  However,  the  advent  of  imaging
modalities  such  as  in  vivo  confocal  microscopy  (IVCM)
permit comprehensive characterization of these vesicular or
linear  deposits  [19-22],  enabling  clarification  of  the
phenotype in situ. This is particularly useful for very mild
disease, and in the absence of a family history.
In this study we aimed to characterize a cohort of New
Zealand patients with PPCD as extensively as possible, from
both  an  ocular  and  systemic  perspective,  and  undertake
mutational analysis of the ZEB1 gene.
METHODS
Eleven (n=11) probands with a diagnosis of PPCD, were
recruited from the Ophthalmology Department of Auckland
District Health Board over a 12 month period and reviewed
in the University Clinic, Dept of Ophthalmology, University
of  Auckland.  Family  members  were  also  recruited  where
available.  The  study  design  adhered  to  the  tenets  of  the
Declaration of Helsinki with Institutional Research Ethics
Board approval (NTX/06/12/161), and all patients provided
informed consent before being entered into this study.
Questionnaire: All subjects completed a general health
questionnaire  which  included  specific  questions  based  on
associations  of  PPCD  described  in  earlier  publications
[11-13], specifically regarding the presence of specific soft
tissue  abnormalities  (hernia,  hydrocoele,  Dupuytren’s
contracture,  bony  lumps,  Osgood-Schlatter  disease,  and
spinal changes), as well as hearing problems, otosclerosis, and
kidney disease.
Clinical:  All  subjects  underwent  extensive  clinical
examination including Snellen visual acuity, auto-refraction,
corneal  topography,  and  pachymetry  using  a  combined
Placido/slit-scanning elevation tomography system (Orbscan
II;  Bausch  &  Lomb  Surgical,  Rochester,  NY),  slit  lamp
examination  and  photography,  and  laser  scanning  in  vivo
confocal microscopy (IVCM) using the HRTII (Heidelberg
Retina  Tomograph  II,  Rostock  Corneal  Module  (RCM)
(Heidelberg  Engineering  GmbH,  Heidelberg,  Germany).
Peripheral venous blood samples were obtained for DNA
extraction.
Molecular:  DNA  extraction  from  blood  used  the  salt
extraction method [23]. PCR amplification of all nine ZEB1
exons and flanking intronic regions was undertaken in all
samples using previously described primers and conditions
(Exon 1 [11], Exons 2-9 [12]). Following column purification
with the HighPure PCR purification kit (Roche Diagnostic,
Mannheim,  Germany),  product  was  sequenced  directly
according  to  protocols  accompanying  the  ABI  BigDye
TABLE 1. DEMOGRAPHIC AND OCULAR DATA FOR ELEVEN SUBJECTS WITH PPCD.
Orbscan II
topography
     CCT
Orbscan II
topography
 thinnest
 
Patient
number          Sex Age Ancestry
RE
BCVA
LE
BCVA RE LE RE LE
Family
history
1 M 37 Caucasian 6/6 6/6 495 482 488 479 1650 x Y - CDB
2 M 10 NZ Maori 6/6- 6/7.5 511 562 506 539 x 2358.3 Y
3 M 48 Polynesian 6/3.8 6/120 x          530             x              524                   x                   1783.33                   N 
4 F 80 Caucasian 6/9 6/9 x x x x 816.667 x N
5 M 57 Caucasian 6/3.8 6/3.8 558x550 x 1225 883.33 NK
6 M 45 Caucasian 6/6 6/15 594 631 583 623 1466.67 1991.67 Y
6a F 12 Caucasian 6/18 6/18 646 638 637 628 1133.333 x Y
7 F 51 Caucasian 6/4.8 6/4.8 628 608 611 591 1191.667 2716.67 N
8 F 18 Caucasian 6/15 6/6 534 517 527 508 1366.67 x Y
9 F 56 Caucasian 6/3.8 6/6 553 553 536 542 2100 1233.33 N
10 F 34 Caucasian 66/4.8 6/9 x x x x 2800 1291.67 N
11 M 32 Tongan 6/6 6/7.5 xxx x x x NK
In the table, M = male and F = female, Age is in years, RE = Right eye, LE = left eye, BCVA = best corrected visual acuity,
CCT = central corneal thickness, measured in microns, x = information not recordable, or not obtained. Y = yes, N = no, NK =
not known, CDB = corneal dystrophy of Bowman Layer. Comment patient #3; LE had penetrating keratoplasty following blunt
trauma, PPD in RE.
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Endothelial cell densityTerminator kit v3.1. Bidirectional sequencing of amplicons
was  undertaken  on  an  ABI  3100  prism  genetic  analyzer
(Applied  Biosystems  Inc,  Foster  City,  CA).  Nucleotide
sequences were compared manually and with CodonCode
Aligner  v.2.0.6  (CodonCode,  Dedham,  MA)  against  the
published ZEB1 genomic DNA (GenBank NC_000010.9),
and  complementary  DNA  (cDNA)  reference  sequence
(NM_030751.4). This variant (2) uses an alternate in-frame
exon, compared to variant 1, resulting in a longer protein
(isoform  b)  with  a  distinct  NH2-terminus,  compared  to
isoform a. When a sequence variant was confirmed, family
members  were  tested  to  determine  segregation  with  the
disease.
The exon 1 sequence variant was screened for by NLAIII
restriction enzyme digest in 50 unaffected control individuals
(100 control chromosomes) using the following Digest mix:
9 μl PCR product, 0.2 μl NLAII enzyme, 0.12 μl BSA, 1.2
μl NE buffer 4, and 1.48 μl sterile water. This was digested
overnight at 37 °C, 2ul BlueJuiceTM (Invitrogen, Carlsbad,
CA) added to each reaction tube, and run on a 3% agarose gel.
RESULTS
Eleven  probands  were  recruited;  their  demographics  and
clinical details are listed in Table 1. Four additional affected
family members were identified, such that the cohort included
four  familial  and  seven  sporadic  cases.  Three  of  the
individuals were of Polynesian ancestry. (New Zealand Maori
n=1,  Samoan  n=1,  Tongan  n=1)  All  of  the  cases  were
determined to be PPCD on the basis of family history when
present,  bilaterality,  exclusion  of  birth  trauma  or  forceps
delivery,  and  typical  features  observed  on  slit-lamp  and
Figure 1. Slit lamp photographs of three
corneas  demonstrating  variation  in
corneal phenotype in PPCD Top row: R
and L cornea of Patient #5, scattered
vesicular  endothelial  lesions  Middle
row: Patient #2 Retroillumination and
direct slit lamp of a band lesion, with a
gray  halo  surrounding  lesion  Bottom
row: Band or railroad track phenotype
in  Patient  #7,  with  thickened
Descemet’s membrane at the edges of
the  band.  LE  shows  small  isolated
vesicular lesions.
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2546IVCM.  Clinical  appearances  of  corneas  and  variable
phenotypes are demonstrated in Figure 1 and Figure 2.
IVCM in all patients demonstrated abnormal endothelial
appearances (Figure 2 and Figure 3). Vesicular PPCD lesions
appeared as focal circular or elliptical regions with hypo-
reflective centers and scalloped borders. These lesions were
often surrounded by hyper-reflective “halos” in the overlying
Descemet’s  membrane,  correlating  with  the  “grey  halos”
observed on slit-lamp biomicroscopy. Band lesions exhibited
well defined borders with abnormal dimpling of endothelial
cells  within  the  band  and  hyper-reflectivity  of  overlying
Descemet’s  membrane.  Undulation  of  the  Descemet
membrane and the endothelial surface were observed in the
region of PPCD lesions.
Bidirectional  sequencing  of  ZEB1  identified  non-
pathogenic sequence variations, and one probable disease-
causing novel sequence variation c.1A→G which results in
the  protein  change  p.1Met→Val.  (Figure  4;
electropherogram) This change segregated with disease in the
family, and was not observed in 100 control chromosomes.
Other non pathogenic sequence variations/single nucleotide
polymorphisms  (SNPs)  detected  have  been  previously
described and are listed in Table 2.
Prediction of potential coding fragment in the reference
mRNA (NM_0030751.4) sequence containing the c.1A→G
was performed using the BESTORF program (Softberry.Inc,
Mount  Kisco,  NY),  and  predicted  translation  initiation  at
nucleotide 788 which encodes the methionine 219 in exon 6,
resulting  in  the  normal  1124  amino  acid  protein  being
truncated  by  218  amino  acids  at  the  COOH-terminus.
Homology  modeling  shows  this  initiating  methionine  is
highly conserved in seven vertebrate species (Figure 5).
Figure 2. Phenotype of family members
with  ZEB1  p.1Met→Val  mutation:
Upper Row: Daughter (Patient #6a) age
12:  slit  lamp  images  of  cornea  with
prominent nerves, diffuse haze. Middle
Row: Father (Patient #6) age 45 more
diffuse clouding with isolated vesicles
and  prominent  corneal  nerves.  Lower
Row: father (Patient #6) IVCM.
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2547Figure 3. IVCM images of phenotypes
of PPCD. Vesicular type: A, B (Patient
#5) and C, D (Patient #1) - vesicular
type. A is at the level of DM, showing a
row of focal elliptical vesicular lesions,
each has a hyper-reflective halo. B is at
the level of the endothelium. Vesicular
lesions have hypo-reflective centers and
scalloped  borders.  C:  multiple  small
focal vesicular endothelial lesions. Band
Type E, F (Patient #7) and G, H (Patient
#4). E shows the edge of a band lesion.
It demonstrates the undulation of DM
and endothelial surface. F: this image
from  within  a  band  demonstrates
abnormal dimpling of endothelial cells.
G shows the edge of a band lesion. It
demonstrates the undulation of DM and
endothelial surface and hyper-reflective
DM.  H:  within  the  band  lesion.
Abnormal dimpling of endothelial cells
with hyper-reflectivity of the overlying
Descemet's membrane. (Each image is
400 µm×400 µm.)
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The zinc E-finger homeodomain binding box protein ZEB1
located  on  chromosome  10p11  was  previously  known  as
transcription  factor  8  (TCF8)  as  it  represses  the  T-
lymphocyte-specific IL2 gene (OMIM 147680) expression
[24].  This  transcription  factor  plays  a  critical  role  in
embryonic development, specifically in the regulation of type
I collagen expression and in the repression of the epithelial
phenotype,  which  is  critical  for  the  maintenance  of  an
endothelial phenotype.
One of the major morphologic abnormalities in PPCD is
the transformation of the endothelium into cells with epithelial
characteristics. Ultrastructurally, this appears as focal loss and
degeneration of the endothelial cell monolayer, several layers
of  stratified  squamous  cells  containing  tonofilaments,
desmosomal  attachments  and  cytokeratin,  as  well  as
microvilli  projecting  into  the  anterior  chamber  [18].
Immunohistochemical  analysis  of  this  abnormal  posterior
corneal  surface  with  cytokeratin  staining  shows  a
predominance of CK7 and CK19 – epithelial cell markers
usually present in ductal and glandular epithelia [25].
Descemet’s  membrane  (DM)  also  demonstrates
abnormal lamination and abnormal deposition of fibrillar and
basement  membrane  collagenous  material  in  its  posterior
Figure 4. Electropherograms demonstrating ZEB1 p.1Met>Val mutation in exon 1. A: Wild-type sequence, B: Mutant heterozygote with c.
1A>G demonstrated with bidirectional sequencing.
TABLE 2. SNPS AND MUTATION TABLE.
Pathogenic variant Non-pathogenic sequence variants
Patient ID Exon 1 Exon 3 Exon 6
1   c.260-538C>T, het c.685-15G>A, hom
2   c.260-154A>G, het c.685-15G>A, het
3     c.685-15G>A, hom
4   c.260-154A>G, het c.685-15G>A, hom
5     c.685-15G>A, het
6 c.1A>G het, p.Met1Val   c.685-15G>A, hom
6a c.1A>G het, p.Met1Val   c.685-15G>A, hom
7     c.685-15G>A, het
8     c.685-15G>A, hom
9     c.685-15G>A, het
10     c.685-15G>A, hom
11   c.260-154A>G, het c.685-15G>A, hom
No sequence variant detected in exons 2,4,5,7-9. In the table, “het” represents heterozygous and “hom” represents homozygous
sequence variant.
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guttata [18]. However, it has been proposed that the change
in Descemet in PPCD is a secondary response to a stressed
endothelium [16].
A complex binding site for ZEB1 protein exists in the
promoter of a collagen gene, COL4A3, which is linked to the
autosomal recessive form of Alport syndrome [12]. Notably,
type  IV  collagen  is  a  major  component  of  basement
membranes.
For mutational analysis of any gene in a given disease to
be meaningful, the phenotype should be well-defined, in an
effort to avoid phenocopies. This may be troublesome when
considerable variability in phenotypic expression exists, as in
PPCD. All of our probands had bilateral disease, with the
characteristic vesicular, band, or diffuse appearance at the
level of the endothelium, frequently associated with a gray
halo surrounding the lesions at the level of DM. The IVCM
changes  observed  are  consistent  with  those  previously
described [19-22]. A differential diagnosis of PPCD includes
birth trauma or tears in DM from forceps delivery or Haab’s
striae in congenital glaucoma. We excluded traumatic birth
history or forceps delivery in all our probands, although this
may be subject to recall bias. Differentiation between these
entities  can  also  well  delineated  by  clinical  appearance,
progression  and  associations,  histopathologically,  and  by
IVCM [26-28].
In delivery forceps related injury, a hypertrophic ridge of
the Descemet membrane may be identified by IVCM [28]. In
Haab’s striae there is usually associated megalocornea, and
on IVCM the striae appear as highly reflective acellular scar
tissue  with  undefined  borders  located  anterior  to  the
endothelial layer, extending toward the posterior stroma. In
addition, the mean keratocyte density of the posterior stroma
is  reduced,  and  stromal  nerve  fibers  show  an  abnormal
morphology of convoluted “coil-shaped” nerves [27].
An absence of family history is not uncommon in PPCD,
and has previously been demonstrated in association with
ZEB1 mutations [11]. This may be partly attributed to lack of
ocular symptoms and mild clinical phenotypes potentially
being overlooked on examination, however, nonpenetrance is
also reported in ZEB1 associated PPCD [12,13], therefore
where possible thorough genotyping and phenotyping should
be performed on all relatives.
An overlap with other clinical phenotypes and PPCD
exists,  in  particular  with  FECD,  the  association  being
strengthened  by  early  reports  reporting  mutations  in  the
COL8A2  both  in  PPCD  and  FECD,  suggesting  a  similar
etiology  [7].  The  authors  suggested  that  underlying
disturbance of the role of type VIII collagen in influencing the
terminal differentiation of the neural crest derived corneal
endothelial cell contributed to these disorders. In addition,
these diseases share features of endothelial metaplasia and
secretion of an abnormal Descemet membrane in the form of
a posterior collagenous layer with a small or absent posterior
non-banded  zone,  which  contains  Type  VIII  collagen  -
normally only seen in the anterior banded component [29].
Indeed,  ocular  characteristics  related  to  PPCD  have  been
reported in relatives of patients with FECD and vice versa
[30]. Mutational analysis of ZEB1 in a Chinese population
with late onset FECD identified one mutation, suggesting it is
not a major contributor to FECD [30].
The frequency of ZEB1 mutations in PPCD cohorts has
varied considerably amongst the reports available to date, and
these frequencies are summarized in Table 3. Initial studies
had small cohorts with high mutational frequencies (40-45%)
[12,13]. The largest published series to date, demonstrated
eight unique mutations (25%) in 32 probands [11], and one
other study similarly demonstrated mutations in 5/29 =17.3%
PPCD [31]. The low frequency observed in our cohort is
predominantly explained by the sample size, but yet again
highlights the genetic heterogeneity of this corneal disorder.
Founder effect is unlikely to be a contributory factor however
as  all  the  mutations  identified  to  date  have  been  unique.
Notably, the ethnic mix of our population varies from the
Caucasian cohorts reported, specifically with the inclusion of
three  Polynesian  individuals  (NZ  Maori,  Tongan,  and
Samoan).
The observation of a non-ocular phenotype associated
with PPCD manifesting as inguinal hernias/ hydroceles/ bony
abnormalities  has  been  replicated  [11,12]  as  has  the
observation of nonpenetrance [12,13] and mutations present
in isolated, apparently non-familial cases [11,12]. Only one
inguinal hernia was present in our cohort, and did not occur
in conjunction with ZEB1 disease.
All of the mutations described to date are unique; many
are frameshift and nonsense with some missense mutations -
the majority occurring in the largest exon, (Exon 7) which
contains the homeodomain and five zinc finger domains. The
c.1A→G missense transition observed in the reported cohort
Figure 5. Homology modeling demonstrates conservation of the initiating methionine in seven vertebrate species.
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mutations involving the initiating methionine are reported –
p.Met1Arg , c.2T→G) [11] and p.Met1Thr, c.2T→C [31].
This is the only amino acid residue where numerous mutations
are  reported,  suggesting  this  may  be  a  “hot  spot”,  as  is
observed with the 124 and 555 arginine in TGFBI - associated
corneal dystrophies [32]. The clinical phenotype segregating
with the p.Met1Arg and p.Met1Thr mutations was however
not clearly characterized, so it is not clear if the p.1Met→Val
phenotype is similar or different to these entities.
The predicted effects of this mutation will result in a
COOH-terminal truncated protein, as translation will likely be
initiated further downstream. Initiation of translation by the
40S ribosomal subunits does not begin at the first ATG (AUG
of mRNA) observed, but rather the optimal ATG initiating
codon and flanking sequence, known as a Kozak sequence. A
purine at position -3 and a guanine at position +4 contribute
significantly to enhance the translation efficiency [33-35].
This optimal context has been determined to be CCNCCAUG.
The first disease described with a mutation in the Kozak
sequence was Beta-thalassemia [36] and subsequently it has
been  identified  in  a  range  of  disorders  including  Peters
anomaly [37], low bone density [38], and Graves’ disease
[39]. Prediction of the next Kozak sequence, using BESTORF
program suggests the resultant protein would be 906 amino
acids long and commence at the nucleotide 788 (wild-type
AGGATCATGG  with  subsequent  production  of  a
CGTCACATGA).  Whether  this  truncated  protein  is
functional has not been determined.
This series of patients not only describes a novel mutation
within ZEB1 in PPCD, but is unique in several other ways. It
also highlights the genetic heterogeneity of PPCD. Although
the individual series reported are too small to accurately assess
prevalence, it is possible that population specific variances in
ZEB1-related PPCD exists.
This  is  the  first  of  the  published  studies  that  clearly
demonstrates in vivo confocal microscopy observations in all
of the patients with PPCD, thereby excluding other similar,
potentially  confusing  pathologies,  such  as  corneal  birth-
forceps injury. This level of phenotypic scrutiny has not been
described  before  in  association  with  mutational  analysis.
Similarly this PPCD cohort was specifically questioned about
non-ocular phenotypes, whereas this was not recorded in the
Shah  series  [31].  Key  corneal  characteristics,  such  as
endothelial count and pachymetry, have not been routinely
included  in  previous  publications  and  relatively  brief
descriptions of the corneal phenotypes segregating with the
TCF8 mutations are described in two major studies [11,13],
and the third concludes that “the PPCD3 ocular phenotype
resulting from TCF8 mutation appears to be a simple PPCD
phenotype,  although  it  shows  great  variation  in  range  of
severity” [12]. Unfortunately, in this latter study, no images
are provided; there are no IVCM data, and there are no details
regarding variation in endothelial count or corneal thickness.
The published data thus far on the genetic contributions
of  ZEB1,  in  the  context  of  our  knowledge  of  VSX1  and
COL8A2,  suggest  and  highlight  that  PPCD  represents  a
complex  disease  with  a  great  amount  of  genetic  and
phenotypic  heterogeneity.  Although  there  appears  to  be  a
strong association with a non-ocular phenotype with ZEB1
mutations, this was not obvious in our cohort. Similarly the
ZEB1 ocular phenotype does not appear to be distinctive to
allow it to be delineated clinically from the other forms of
PPCD. On-going genotyping and development of enhanced
phenotyping  tools  may  allow  this  distinction  to  be  better
clarified.
Analysis  of  ZEB1  in  this  cohort  of  PPCD  patients
confirms  the  pathogenicity  of  this  gene  but  suggests  the
frequency  differs  between  populations.  Combining  the  5
series to date, including this series, suggests ZEB1 mutations
in PPCD probably accounts for 25% of the disease. Three of
the reported mutations to date including the novel Met1Thr in
this cohort involve the initiating methionine, suggesting this
site is a potential hot spot. ZEB1 therefore is one of the more
significant genes identified to date in the pathogenesis of this
disease.
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